These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 27347680)

  • 1. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
    Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL
    PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice.
    Chen G; Yu Y; Zhu Y; Nagashimada M; Wang Y; Nagata N; Xu L
    Endocrinology; 2024 May; 165(7):. PubMed ID: 38862137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
    Tacke F
    Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
    Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
    Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
    Ratziu V; Sanyal A; Harrison SA; Wong VW; Francque S; Goodman Z; Aithal GP; Kowdley KV; Seyedkazemi S; Fischer L; Loomba R; Abdelmalek MF; Tacke F
    Hepatology; 2020 Sep; 72(3):892-905. PubMed ID: 31943293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
    Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
    J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
    Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
    Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis.
    Song X; Jiang C; Yu M; Lu C; He X
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1597-1605. PubMed ID: 38744472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of intrahepatic monocyte recruitment by Cenicriviroc and extracellular matrix degradation by MMP1 synergistically attenuate liver inflammation and fibrogenesis in vivo.
    Geervliet E; Karkdijk E; Bansal R
    Sci Rep; 2024 Jul; 14(1):16897. PubMed ID: 39043893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice.
    Ambade A; Lowe P; Kodys K; Catalano D; Gyongyosi B; Cho Y; Iracheta-Vellve A; Adejumo A; Saha B; Calenda C; Mehta J; Lefebvre E; Vig P; Szabo G
    Hepatology; 2019 Mar; 69(3):1105-1121. PubMed ID: 30179264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury.
    Puengel T; Krenkel O; Kohlhepp M; Lefebvre E; Luedde T; Trautwein C; Tacke F
    PLoS One; 2017; 12(9):e0184694. PubMed ID: 28910354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
    Friedman SL; Ratziu V; Harrison SA; Abdelmalek MF; Aithal GP; Caballeria J; Francque S; Farrell G; Kowdley KV; Craxi A; Simon K; Fischer L; Melchor-Khan L; Vest J; Wiens BL; Vig P; Seyedkazemi S; Goodman Z; Wong VW; Loomba R; Tacke F; Sanyal A; Lefebvre E
    Hepatology; 2018 May; 67(5):1754-1767. PubMed ID: 28833331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy.
    Kwiatkowski K; Pawlik K; Ciapała K; Piotrowska A; Makuch W; Mika J
    Front Immunol; 2020; 11():615327. PubMed ID: 33408720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic alcohol-induced neuroinflammation involves CCR2/5-dependent peripheral macrophage infiltration and microglia alterations.
    Lowe PP; Morel C; Ambade A; Iracheta-Vellve A; Kwiatkowski E; Satishchandran A; Furi I; Cho Y; Gyongyosi B; Catalano D; Lefebvre E; Fischer L; Seyedkazemi S; Schafer DP; Szabo G
    J Neuroinflammation; 2020 Oct; 17(1):296. PubMed ID: 33036616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells.
    Madan U; Verma B; Awasthi A
    Eur J Immunol; 2024 Jul; 54(7):e2350847. PubMed ID: 38643381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A New Application for Cenicriviroc, a Dual CCR2/CCR5 Antagonist, in the Treatment of Painful Diabetic Neuropathy in a Mouse Model.
    Bober A; Piotrowska A; Pawlik K; Ciapała K; Maciuszek M; Makuch W; Mika J
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy.
    Bowler S; Siriwardhana C; Mitchell BI; D'Antoni ML; Ogata-Arakaki D; Souza S; Yee R; Gangcuangco LMA; Chow DC; Ndhlovu LC; Shikuma C
    HIV Res Clin Pract; 2019; 20(4-5):123-129. PubMed ID: 32013805
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
    Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.
    D'Antoni ML; Mitchell BI; McCurdy S; Byron MM; Ogata-Arakaki D; Chow D; Mehta NN; Boisvert WA; Lefebvre E; Shikuma CM; Ndhlovu LC; Baumer Y
    J Leukoc Biol; 2018 Dec; 104(6):1241-1252. PubMed ID: 30088682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.